What Would It Take For Eli Lilly Stock To Keep Climbing?

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

What Would Double Eli Lilly's Revenue From Here?

Almost all of the upside is revenue. The scenario caps growth at 30% a year. That is well below the 49.6% Lilly grew over the past twelve months, though only a little below the roughly 32% pace of its own 2026 guide. Revenue still climbs from $79.7 billion to $175.0 billion by year three.

The engine is incretins. Mounjaro and Zepbound together made $14.9 billion in the second quarter of 2026, $6.3 billion more than a year earlier. Net margin eases to 30.7% in the scenario, so earnings roughly double.

Then the multiple takes its cut. Lilly's P/E of 38.5x already sits below its three-year average of 68.9x, and the scenario trims it further to 33.6x because slower growth will not support even today's multiple. On those assumptions the stock would be worth about $2,024 in three years, roughly 76% above today.

Does Foundayo Have To Work For That Math To Hold?

Year one is well-anchored by current guidance. Lilly's 2026 revenue guidance, raised in August 2026, is a one-year pace of about 32% against the last reported year. The scenario runs at 30% a year, so the two are close: on the guided path the upside is 78% instead of 76%.

Years two and three are where Foundayo comes in. Management recently said that the pill had gone from 8,000 U.S. prescribers to 36,000, and that it is under regulatory review in more than 40 additional countries, with most launches due in 2027. Lilly next reports on October 29, 2026, when the trailing revenue and margin figures above refresh.

The margin is the soft spot. Net margin of 33.5% over the trailing twelve months sits near its three-year peak, well above the 24.2% three-year average. Put it back at that average and the upside falls from 76% to 38%.

Management's own margin guidance moved the other way: on the August 2026 call Lilly raised its 2026 non-GAAP performance margin range two points at each end, to 49% to 50.5%. Performance margin is a company-defined measure, not the net margin above. But two things push on the net margin. In the U.S., volume is doing the work while price is falling . And Lilly is buying growth as well as building it: on that same call, which lifted the revenue guidance, management cut its 2026 earnings-per-share guidance.